Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-2.52%
1,070.19
-27.62
-2.52%
—1,097.811,087.761,087.761,068.56——
SIXC
Communications
SIXC
Communications
SIXC
-0.63%
608.20
-3.83
-0.63%
—612.03612.03612.03606.60——
SIXE
Energy
SIXE
Energy
SIXE
+1.51%
1,238.91
+18.48
+1.51%
—1,220.431,221.991,240.941,221.99——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.99%
1,724.51
-35.01
-1.99%
—1,759.521,754.311,754.311,724.51——
SIXM
Financials
SIXM
Financials
SIXM
-0.25%
629.96
-1.58
-0.25%
—631.54631.27633.99628.63——
SIXR
Staples
SIXR
Staples
SIXR
-0.27%
854.85
-2.31
-0.27%
—857.16858.91861.71852.33——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-1.48%
212.23
-3.18
-1.48%
—215.41215.41215.41211.92——
SIXT
Technology
SIXT
Technology
SIXT
-0.76%
3,586.64
-27.51
-0.76%
—3,614.153,556.243,590.323,516.86——
SIXU
Utilities
SIXU
Utilities
SIXU
-2.40%
886.53
-21.77
-2.40%
—908.30906.55906.55885.88——
SIXV
Health care
SIXV
Health care
SIXV
-1.01%
1,465.47
-14.93
-1.01%
—1,480.401,479.551,484.431,464.92——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.53%
2,361.69
-36.68
-1.53%
—2,398.372,373.092,373.092,350.27——
LSTA:NASDAQ
Lisata Therapeutics Inc
$3.18
+3.25%
(+0.10) 1D
May 15, 12:55:37 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LSTA...
Open
$3.02
High
$3.18
Low
$3.02
Mkt. cap
28.96M
Avg. vol.
77.72K
Volume
10.84K
52-wk high
$5.07
52-wk low
$1.81
EPS
-$1.91
Beta
0.81
Shares outstanding
9.11M
No. of employees
21
News stories
From sources across the web
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics Inc
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, New Jersey, United States
SectorBiotechnology
Websitelisata.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
70.00K
-
100.00K
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2.25M
1.96M
1.13M
1.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.68M
2.46M
2.04M
3.74M
Operating expense
4.94M
4.41M
3.18M
4.94M
Total operating expenses
4.94M
4.41M
3.18M
4.94M
Operating income
-4.87M
-4.41M
-3.08M
-4.94M
Other non operating income
-7.00K
-18.00K
-16.00K
-54.00K
EBT including unusual items
-4.66M
-4.25M
-2.95M
-4.88M
EBT excluding unusual items
-4.66M
-4.25M
-2.95M
-4.88M
Income tax expense
-
-
-
-387.00K
Effective tax rate
-
-
-
7.94%
Other operating expenses
-
-
-
-
Net income
-4.66M
-4.25M
-2.95M
-4.49M
Net profit margin
-6,655.71%
-
-2,954.00%
-
Earnings per share
-0.54
-0.49
-
-
Interest and investment income
216.00K
183.00K
141.00K
120.00K
Interest expense
-
-
-
-
Net interest expenses
216.00K
183.00K
141.00K
120.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.82M
-4.37M
-3.06M
-4.94M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer